title: In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
abstract: The in-vitro activity of LY146032 was compared with that of other antibiotics against Gram-positive organisms, mostly isolated from cancer patients. LY146032 inhibited all isolates, including methicillin-resistant Staphylococcus aureus and Streptococcus faecalis, at a concentration of less than or equal to 2.0 mg/l. The MBCs of this new drug were within eight times the MICs for all bacteria tested.
authors.affiliation: Department of Medical Specialties, University of Texas M. D. Anderson Hospital and Tumor Institute, Houston 77030.
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: K V
authors.initials: KV
authors.lastname: Rolston
authors.forename: D H
authors.initials: DH
authors.lastname: Ho
authors.forename: B
authors.initials: B
authors.lastname: LeBlanc
authors.forename: G P
authors.initials: GP
authors.lastname: Bodey
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology; D010455:Peptides / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D010455:Peptides; D017576:Daptomycin